 | ||
| Just Hours Left to See Our Top Picks Zacks Member, Just in case you missed my email earlier today, I wanted to give you one final reminder about a chance to grow your wealth FAST. According to our research, 7 stocks in the Biotech sector are on the brink of major bullish moves. Billions of dollars are being poured into R&D, new clinical trials are beginning, and acquisition rumors are in the air. We expect each of these to deliver impressive long-term gains for investors who buy now. The emergence of COVID kicked medical developments into high gear. And now that we're on the offense against the virus, this is the perfect time for well-placed investments in the Biotech sector. Our resident Biotech expert Kevin Cook just released The Century of Biology: 7 Biotech Stocks to Buy Now (3rd Edition), a brand-new special report that reveals these breakout stocks – including a company that could shoot to the moon as it develops vaccines… for cancer. Recommendations from the 2nd edition of this report soared as much as +205%, +258%, even +477% gains in a matter of just months.¹ This is the most exciting industry in the entire stock market right now. Don't miss out on what could be your most lucrative investments in 2021 (and beyond). This is your last chance to download the report. Click below to see the 7 breakout stocks before the midnight deadline tonight – Sunday, March 28. Good Investing,
| ||
 | ||
| ¹ The results listed above are not (or may not be) representative of the performance of all selections made by Zacks Investment Research's newsletter editors and may represent the partial close of a position. This free resource is being sent by Zacks.com. We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research is not a licensed securities dealer, broker or US investment adviser or investment bank. The Zacks #1 Rank Performance covers the period beginning on January 1, 1988 through March 1, 2021. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank #1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed above. Zacks Emails Zacks Investment Research |
没有评论:
发表评论